Improved prostate cancer diagnostics

Stockholm3 is a blood test that detects the risk of aggressive prostate cancer by combining five protein markers, more than 100 genetic markers, clinical data and a proprietary algorithm. This non-invasive blood test reduces the number of unnecessary biopsies by 50% compared to current clinical practice.

Regional Innovation Scheme (RIS)

The Stockholm3 test also identifies men with aggressive prostate cancer with low PSA values (1-3 ng/ml) which is key for early detection. These test characteristics are unique and open up for a new clinical gold standard test.


The Stockholm3 test combines five protein markers, over 100 genetic markers, clinical data and a proprietary algorithm to detect the risk of aggressive prostrate cancer. The test is based on research conducted at the Karolinska Institutet in collaboration with Thermo Fisher Scientific. Stockhom3 has been validated in a clinical study including more than 58,000 participants. The results have been published in numerous scientific journals, including The Lancet Oncology, Nature Reviews, Clinical Oncology and European Urology Focus. The Stockholm 3 test has been validated in clinical use in Sweden and Norway.

When announcing Stockholm3 as the EIT Innovation Award 2017 winner, the jury said: “The winner demonstrated the uniqueness and originality of the product, and it clearly addresses a market need in the medical field that potentially affects millions of individuals. The innovation has been tested and validated, and the expected societal and economic impact has the potential to be very high.” Stockholm3 is an EIT Health Innovation by Design Project 2017–18.

Watch the video here

Results to date
  • The Stockholm3 test has been available for clinical use in Sweden as a Lab Developed Test (LDT) since May 2016
  • Stockholm3 is being evaluated by the Swedish National Board of Health and Welfare for potential use in a national screening programme by invitation
  • Discussions with potential international lab-providers have been initiated
  • The Stockholm3 test is currently being implemented in Norway and preparations are in place to initiate implementation studies in Germany, Holland, Belgium and Finland.
  • Stockholm3 was awarded the EIT Innovation Award 2017 in Budapest in October.
  • At the 9th European Multidisciplinary Meeting on Urological Cancers (EMUC17) in Barcelona, Spain in December 2017, the company was selected for the top prize.

When accepting the EIT Innovation Award 2017, Stockholm3’s Martin Steinberg (pictured above) said: “EIT Health has been a catalyst for this project, and for the close collaboration between academia, industry and healthcare providers we needed for testing, validation and market access. With the support of EIT Health, we are accelerating the implementation of Stockholm3, which has the potential to save 500,000 men from unnecessary treatments with severe side effects if implemented broadly in Europe.”

Societal impact

By reducing unnecessary biopsies and treatments by more than 50% and mortality up to 20%, the STOCKHOLM3 test will have significant positive impact on the society by reducing individual harm based on over-diagnosis, mortality and overall healthcare costs.

  • More men with aggressive cancers will be detected early and thus have a higher chance of survival

  • The economic burden for payers/society will be significantly reduced. This will be due to fewer biopsies and less unnecessary curative treatments, active surveillance of insignificant tumors and procedure related morbidity.

Benefits of EIT Health support

Stockholm3 is a two-year Innovation by Design project that started in January 2017. The catalytic funding from EIT Health and the health care and academic networks included in EIT Health have made it possible to implement and assess prototypes, fine tune product offerings and provide the first individualised and integrated prostate cancer risk score that could change society’s view on prostate cancer.

EIT Health has thus provided three clear values to the project:

  1. Catalyst for HCP/industry/academia cooperation for testing, validation and market access

  2. Vehicle to accelerate the uptake and acceptance of the concept

  3. Additional financing to facilitate the partnership in the project

Location: Stockholm, Sweden

EIT Health Partners involved
  • Erasmus University Medical Center Rotterdam
  • Friedrich-Alexander-Universität Erlangen-Nürnberg
  • Ghent University
  • Janssen-Cilag Gmbh
  • Karolinska Institutet
  • KU Leuven
  • Stockholm County Council
  • Thermo Fisher Scientific-Phadia AB
  • University Medical Center Groningen (UMCG)

More information: